ライフサイエンスコーパス: neutropenic fever

1 16 patients [50%], with six [19%] developing neutropenic fever).

2 ms commonly used in the empiric treatment of neutropenic fever.

3 ncluded one grade 4 diarrhea and one grade 4 neutropenic fever.

4 3, n = 20 [33%]; grade 4, n = 2 [3%]) but no neutropenic fever.

5 nd 3% of patients receiving TAP experiencing neutropenic fever.

6 ut was manageable with only a single case of neutropenic fever.

7 amycin-piperacillin for empirical therapy of neutropenic fever.

8 nsisting of thrombocytopenia associated with neutropenic fever.

9 owever, it did not increase the incidence of neutropenic fever.

10 No patient required hospitalization for neutropenic fever.

11 Only one patient was hospitalized for neutropenic fever.

12 dose-limiting toxic effects of mucositis and neutropenic fever.

13 omplicated by hospitalization, primarily for neutropenic fever.

14 g/m2, at which level two of six patients had neutropenic fever.

15 was tolerable, with the major toxicity being neutropenic fever.

16 (51%) required dose reductions, usually for neutropenic fever.

17 vely), and one patient in each group died of neutropenic fevers.

18 Acute toxicities during TPE included neutropenic fever (10%) and during XPE, grade 3 or 4 ora

19 de >/=3 adverse events were pneumonia (20%), neutropenic fever (11%), and diarrhea (6%).

20 related to neutropenia present at baseline: neutropenic fever (13 of 25 subjects) and septic death (

21 (3.3% v 0.0%; P =.004), hospitalizations for neutropenic fever (13.4% v 1.5%; P <.001), hospitalizati

22 for toxicity, which included 11 patients for neutropenic fever (18%).

23 events included fatigue (5%), vomiting (2%), neutropenic fever (2%), and neutropenia (2%).

24 ), thrombocytopenia (12%), anemia (12%), and neutropenic fever (2%).

25 significant (severe) adverse events included neutropenic fever (24% of patients), asthenia (22%), inf

26 bocytopenia: grade 3, 26%; grade 4, 3%), but neutropenic fever (6%) and bleeding events (0%) were rar

27 s, moderate to severe neutropenia (38%), and neutropenic fever (6%).

28 s was observed after 4%, infection after 3%, neutropenic fever after 6%, neutrophils less than 100/mi

29 microg/kg did not reduce the probability of neutropenic fever after high-dose paclitaxel.

30 The incidence of neutropenic fever after the first cycle of paclitaxel 25

31 nd day 8 of chemotherapy, respectively, with neutropenic fever and abdominal pain; the third patient

32 Filgrastim largely obviates neutropenic fever and allows for the single-agent dose-i

33 , one from necrotic bowel and the other from neutropenic fever and colitis.

34 Four patients experienced neutropenic fever and one had mild bronchospasm.

35 well tolerated with anticipated cytopenias, neutropenic fever, and disease-related fever, diarrhea,

36 herapy was well tolerated, with transfusion, neutropenic fever, and infection remaining the most freq

37 One had non-neutropenic fever, another had neutropenic fever, and the third was afebrile and non-ne

38 n of prophylactic antibiotics, management of neutropenic fevers, and transfusion support.

39 One had non-neutropenic fever, another had neutropenic fever, and th

40 mucositis of varying degrees, diarrhea, and neutropenic fever, but all patients recovered.

41 s among treatment groups in the incidence of neutropenic fever, days of hospitalization, or number of

42 n C were admitted to the hospital because of neutropenic fever for a median duration of 4 days (range

43 ohort, these infections were associated with neutropenic fever from an enteric source, and most isola

44 Only four of 121 patients (3.3%) developed neutropenic fever (grade 4 neutropenia with > or = grade

45 ogic or electrolyte abnormalities, including neutropenic fever in 18%.

46 ppression was the major adverse effect, with neutropenic fever in 28 (23%) of 124 courses of therapy.

47 hairy cell leukemia (HCL) is complicated by neutropenic fever in 42% of patients despite documented

48 ia or arthralgia in 30%, neutropenia in 53%, neutropenic fever in 8%, and thrombocytopenia in 42% of

49 adverse events that was most pronounced for neutropenic fever/infections and gastrointestinal events

50 rade 3 hypersensitivity reaction (n = 1) and neutropenic fever (n = 1), both at 10 mg/kg.

51 common grade 3-4 adverse events overall were neutropenic fever (n=27) and pneumonia (n=18).

52 -associated thrombosis, leukemic meningitis, neutropenic fever, neutropenic enterocolitis, and transf

53 However, neither neutropenic fever nor episodes of bleeding were major oc

54 Major infections or neutropenic fever occurred in 13% of patients.

55 ts) was transient grades 3 to 4 neutropenia; neutropenic fever occurred in 27%.

56 There was no neutropenic fever or neutropenic sepsis.

57 ays, and 9 (38%) patients did not experience neutropenic fevers or require broad-spectrum antibiotics

58 es were observed in 10% of patients, with no neutropenic fevers or treatment-related death.

59 with bleeding, grade 3 or 4 renal toxicity, neutropenic fever, or mucositis) was observed in 9.3% of

60 Grade 3 or 4 neutropenic fevers (P=0.01), nausea and vomiting (P<0.00

61 Neutropenic fever requiring hospitalization occurred in

62 on therapy, whereas myalgia, arthralgia, and neutropenic fever/sepsis were more common with single-ag

63 nia (P <.0001) leading to significantly less neutropenic fever/sepsis.

64 Four patients had neutropenic fever that required hospitalization, and sev

65 lantation, 13 patients were hospitalized for neutropenic fever, thrombocytopenia, or both.

66 c: grade 3/4 neutropenia, four patients (one neutropenic fever); two patients had grade 3 thrombocyto

67 The incidence of neutropenic fevers was less than 5% in both arms.

68 However, the incidence of neutropenic fevers was similar between the two groups (8

69 e 3 or 4 mucositis, grade 4 neutropenia, and neutropenic fever were less frequent during treatment wi

70 Neutropenic fevers were rare and no intracranial hemorrh

71 The most common toxicity was neutropenic fever, which occurred in 39% of patients.

72 tment breaks were mediport complications and neutropenic fever, which occurred mostly at that dose le

73 All had neutropenic fever with symptoms of mucositis and/or ente

74 One patient developed neutropenic fever without bacteriologic documentation an